Display options
Cite
Rogers EJ, Jada R, Schragenheim-Rozales K, et al. An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors. Front Mol Neurosci. 2019;12:43doi: 10.3389/fnmol.2019.00043.
Rogers, E. J., Jada, R., Schragenheim-Rozales, K., Sah, M., Cortes, M., Florence, M., Levy, N. S., Moss, R., Walikonis, R. S., Palty, R., Shalgi, R., Lichtman, D., Kavushansky, A., Gerges, N. Z., Kahn, I., Umanah, G. K. E., & Levy, A. P. (2019). An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors. Frontiers in molecular neuroscience, 1243. https://doi.org/10.3389/fnmol.2019.00043
Rogers, Eli J, et al. "An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors." Frontiers in molecular neuroscience vol. 12 (2019): 43. doi: https://doi.org/10.3389/fnmol.2019.00043
Rogers EJ, Jada R, Schragenheim-Rozales K, Sah M, Cortes M, Florence M, Levy NS, Moss R, Walikonis RS, Palty R, Shalgi R, Lichtman D, Kavushansky A, Gerges NZ, Kahn I, Umanah GKE, Levy AP. An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors. Front Mol Neurosci. 2019 Feb 20;12:43. doi: 10.3389/fnmol.2019.00043. eCollection 2019. PMID: 30842726; PMCID: PMC6391579.
Copy Download .nbib Format: NLM
Share it on

Front Mol Neurosci. 2019 Feb 20;12:43. doi: 10.3389/fnmol.2019.00043. eCollection 2019.

An IQSEC2 Mutation Associated With Intellectual Disability and Autism Results in Decreased Surface AMPA Receptors.

Frontiers in molecular neuroscience

Eli J Rogers, Reem Jada, Kinneret Schragenheim-Rozales, Megha Sah, Marisol Cortes, Matthew Florence, Nina S Levy, Rachel Moss, Randall S Walikonis, Raz Palty, Reut Shalgi, Daniela Lichtman, Alexandra Kavushansky, Nashaat Z Gerges, Itamar Kahn, George K E Umanah, Andrew P Levy

Affiliations

  1. Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
  2. Department of Physiology and Neurobiology, University of Connecticut, Storrs, CT, United States.
  3. Department of Neurology, Johns Hopkins University, Baltimore, MD, United States.
  4. Department of Biopharmaceutical Sciences and Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, United States.

PMID: 30842726 PMCID: PMC6391579 DOI: 10.3389/fnmol.2019.00043

Abstract

We have recently described an A350V mutation in IQSEC2 associated with intellectual disability, autism and epilepsy. We sought to understand the molecular pathophysiology of this mutation with the goal of developing targets for drug intervention. We demonstrate here that the A350V mutation results in interference with the binding of apocalmodulin to the IQ domain of IQSEC2. We further demonstrate that this mutation results in constitutive activation of the guanine nucleotide exchange factor (GEF) activity of IQSEC2 resulting in increased production of the active form of Arf6. In a CRISPR generated mouse model of the A350V IQSEC2 mutation, we demonstrate that the surface expression of GluA2 AMPA receptors in mouse hippocampal tissue was significantly reduced in A350V IQSEC2 mutant mice compared to wild type IQSEC2 mice and that there is a significant reduction in basal synaptic transmission in the hippocampus of A350V IQSEC2 mice compared to wild type IQSEC2 mice. Finally, the A350V IQSEC2 mice demonstrated increased activity, abnormal social behavior and learning as compared to wild type IQSEC2 mice. These findings suggest a model of how the A350V mutation in IQSEC2 may mediate disease with implications for targets for drug therapy. These studies provide a paradigm for a personalized approach to precision therapy for a disease that heretofore has no therapy.

Keywords: AMPA; Arf6; GEF; IQ domain; IQSEC2; autism; calmodulin; intellectual disability

References

  1. J Biol Chem. 1999 Mar 12;274(11):6827-30 - PubMed
  2. FEBS Lett. 2002 Feb 20;513(1):107-13 - PubMed
  3. Eur J Pharmacol. 2003 Feb 28;463(1-3):3-33 - PubMed
  4. J Biol Chem. 2003 Oct 24;278(43):41573-6 - PubMed
  5. Exp Toxicol Pathol. 2003 Jul;55(1):69-83 - PubMed
  6. Genes Brain Behav. 2004 Oct;3(5):287-302 - PubMed
  7. Science. 2005 Apr 1;308(5718):83-8 - PubMed
  8. Genes Dev. 2005 Sep 1;19(17):2000-15 - PubMed
  9. Neuron. 2006 Apr 6;50(1):75-88 - PubMed
  10. J Neurosci. 2006 May 3;26(18):4811-9 - PubMed
  11. J Phys Chem B. 2006 May 18;110(19):9728-37 - PubMed
  12. Brain Res. 2006 Nov 20;1120(1):35-45 - PubMed
  13. Nat Protoc. 2006;1(2):848-58 - PubMed
  14. Eur J Cell Biol. 2007 Sep;86(9):513-24 - PubMed
  15. J Biol Chem. 2007 Aug 10;282(32):23316-25 - PubMed
  16. Cell. 2007 Oct 5;131(1):160-73 - PubMed
  17. Neurosci Res. 2008 Feb;60(2):199-212 - PubMed
  18. Science. 2008 Feb 22;319(5866):1104-7 - PubMed
  19. Neuron. 2009 Apr 16;62(1):84-101 - PubMed
  20. J Neurosci. 2009 May 13;29(19):6320-35 - PubMed
  21. Nat Genet. 2010 Jun;42(6):486-8 - PubMed
  22. Neuron. 2010 Jun 10;66(5):768-80 - PubMed
  23. Nat Methods. 2011 Jun 26;8(8):659-61 - PubMed
  24. J Neurosci. 2012 Aug 22;32(34):11716-26 - PubMed
  25. Cell. 2012 Aug 31;150(5):987-1001 - PubMed
  26. Eur J Med Genet. 2015 May;58(5):324-7 - PubMed
  27. Front Mol Neurosci. 2016 Jan 11;8:85 - PubMed
  28. J Neurosci. 2016 Feb 3;36(5):1636-46 - PubMed
  29. Nat Commun. 2016 Mar 24;7:11080 - PubMed
  30. Psychiatr Genet. 2016 Jun;26(3):101-8 - PubMed
  31. Neural Plast. 2016;2016:3204519 - PubMed
  32. Epilepsia. 2016 Nov;57(11):1858-1869 - PubMed
  33. Nat Commun. 2016 Nov 23;7:13583 - PubMed
  34. Neurol Genet. 2017 Feb 01;3(1):e130 - PubMed
  35. Transl Psychiatry. 2017 May 2;7(5):e1110 - PubMed
  36. Clin Case Rep. 2017 Aug 24;5(10):1639-1643 - PubMed
  37. Pediatr Neurol. 2018 Feb;79:69-71 - PubMed
  38. Sci Transl Med. 2017 Dec 13;9(420):null - PubMed
  39. Small GTPases. 2018 Jan 24;:1-7 - PubMed
  40. Brain. 2018 Mar 1;141(3):651-661 - PubMed
  41. Brain Behav. 2017 Dec 19;8(1):e00895 - PubMed
  42. Neuropsychopharmacology. 2019 Jan;44(2):314-323 - PubMed
  43. Nat Genet. 2018 Jul;50(7):1048-1053 - PubMed
  44. Front Mol Neurosci. 2018 Jul 06;11:223 - PubMed
  45. Genet Med. 2018 Sep 12;:null - PubMed
  46. Hum Mutat. 2019 Jan;40(1):5-24 - PubMed
  47. Science. 2019 Jan 4;363(6422): - PubMed
  48. Behav Brain Res. 2019 Mar 15;360:209-215 - PubMed
  49. Front Mol Neurosci. 2018 Dec 05;11:440 - PubMed

Publication Types

Grant support